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Abstract
We devise a novel inference algorithm to effectively solve the cancer pro-
gression model reconstruction problem. Our empirical analysis of the ac-
curacy and convergence rate of our algorithm, CAncer PRogression Infer-
ence (CAPRI), shows that it outperforms the state-of-the-art algorithms
addressing similar problems.
Motivation: Several cancer-related genomic data have become avail-
able (e.g., The Cancer Genome Atlas, TCGA) typically involving hun-
dreds of patients. At present, most of these data are aggregated in a
cross-sectional fashion providing all measurements at the time of diagno-
sis.
Our goal is to infer cancer “progression” models from such data. These
models are represented as directed acyclic graphs (DAGs) of collections
of “selectivity” relations, where a mutation in a gene A “selects” for a
later mutation in a gene B. Gaining insight into the structure of such
progressions has the potential to improve both the stratification of patients
and personalized therapy choices.
Results: The CAPRI algorithm relies on a scoring method based on a
probabilistic theory developed by Suppes, coupled with bootstrap and max-
imum likelihood inference. The resulting algorithm is efficient, achieves
high accuracy, and has good complexity, also, in terms of convergence
properties. CAPRI performs especially well in the presence of noise in
the data, and with limited sample sizes. Moreover CAPRI, in contrast to
other approaches, robustly reconstructs different types of confluent tra-
jectories despite irregularities in the data.
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Milan, Italy.
‡Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles,
USA.
§Courant Institute of Mathematical Sciences, New York University, New York, USA
1
We also report on an ongoing investigation using CAPRI to study
atypical Chronic Myeloid Leukemia, in which we uncovered non trivial
selectivity relations and exclusivity patterns among key genomic events.
Availability: CAPRI is part of the TRanslational ONCOlogy R pack-
age and is freely available on the web at:
http://bimib.disco.unimib.it/index.php/Tronco
Contact: daniele.ramazzotti@disco.unimib.it
1 Introduction
Analysis and interpretation of the fast-growing biological data sets that are
currently being curated from laboratories all over the world require sophisticated
computational and statistical methods.
Motivated by the availability of genetic patient data, we focus on the problem
of reconstructing progression models of cancer. In particular, we aim to infer the
plausible sequences of genomic alterations that, by a process of accumulation,
selectively make a tumor fitter to survive, expand and diffuse (i.e., metastasize).
Along the trajectories of progression, a tumor (monotonically) acquires or “ac-
tivates” mutations in the genome, which, in turn, produce progressively more
“viable” clonal subpopulations over the so-called cancer evolutionary landscape
(cfr., [23, 33,49]).
Knowledge of such progression models is very important for drug develop-
ment and in therapeutic decisions. For example, it has been known that for the
same cancer type, patients in different stages of different progressions respond
differently to different treatments.
Several datasets are currently available that aggregate diverse cancer-patient
data and report in-depth mutational profiles, including e.g., structural changes
(e.g., inversions, translocations, copy-number variations) or somatic mutations
(e.g., point mutations, insertions, deletions, etc.). An example of such a dataset
is The Cancer Genome Atlas (TCGA) (cfr., [36])). These data, by their very
nature, only give a snapshot of a given tumor sample, mostly from biopsies of
untreated tumor samples at the time of diagnoses. It still remains impractical
to track the tumor progression in any single patient over time, thus limiting
most analysis methods to work with cross-sectional data1.
To rephrase, we focus on the problem of cancer progression models recon-
struction from cross-sectional data. The problem is not new and, to the best of
our knowledge, two threads of research starting in the late 90’s have addressed it.
The first category of works examined mostly gene-expression data to reconstruct
the temporal ordering of samples (cfr., [16, 31]). The second category of works
looked at inferring cancer progression models of increasing model-complexity,
starting from the simplest tree models (cfr. [9]) to more complex graph models
1Unlike longitudinal studies, these cross-sectional data are derived from samples that are
collected at unknown time points, and can be considered as “static”.
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Figure 1: Selectivity Relation in Tumor Evolution. The CAncer PRogres-
sion Inference (CAPRI) algorithm examines cancer patients’ genomic cross-
sectional data to determine relationships among genomic alterations (e.g., so-
matic mutations, copy-number variations, etc.) that modulate the somatic evo-
lution of a tumor. When CAPRI concludes that aberration a (say, an egfr
mutation) “selects for” aberration b (say, a cdk mutation), such relations can
be rigorously expressed using Suppes’ conditions, which postulates that if a se-
lects b, then a occurs before b (temporal priority) and occurrences of a raises the
probability of emergence of b (probability raising). Moreover, CAPRI is capable
of reconstructing relations among more complex boolean combination of events,
as shown in the bottom panel and discussed in the Approach section.
(cfr., [15]); see the next subsection for an overview of the state of the art. Build-
ing on our previous work described in [37] we present a novel and comprehensive
algorithm of the second category that addresses this problem.
The new algorithm proposed here is called CAncer PRogression Inference
(CAPRI) and is part of the TRanslational ONCOlogy (TRONCO) package
(cfr., [2]). Starting from cross-sectional genomic data, CAPRI reconstructs a
probabilistic progression model by inferring “selectivity relations”, where a mu-
tation in a gene A “selects” for a later mutation in a gene B. These relations are
depicted in a combinatorial graph and resemble the way a mutation exploits its
“selective advantage” to allow its host cells to expand clonally. Among other
things, a selectivity relation implies a putatively invariant temporal structure
among the genomic alterations (i.e., events) in a specific cancer type. In addi-
tion, these relations are expected to also imply “probability raising” for a pair
of events in the following sense: Namely, a selectivity relation between a pair
of events here signifies that the presence of the earlier genomic alteration (i.e.,
the upstream event) that is advantageous in a Darwinian competition scenario
increases the probability with which a subsequent advantageous genomic alter-
ation (i.e., the downstream event) appears in the clonal evolution of the tumor.
Thus the selectivity relation captures the effects of the evolutionary processes,
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and not just correlations among the events and imputed clocks associated with
them. As an example, we show in (Figure 1) the selectivity relation connecting
a mutation of egfr to the mutation of cdk.
Consequently, an inferred selectivity relation suggests mutational profiles
in which certain samples (early-stage patients) display specific alterations only
(e.g., the alteration characterizing the beginning of the progression), while cer-
tain other samples (e.g., late-stage patients) display a superset subsuming the
early mutations (as well as alterations that occur subsequently in the progres-
sion).
Various kinds of genomic aberrations are suitable as input data, and in-
clude somatic point/indel mutations, copy-number alterations, etc., provided
that they are persistent, i.e., once an alteration is acquired no other genomic
event can restore the cell to the non-mutated (i.e., wild type) condition2.
The selectivity relations that CAPRI reconstructs are ranked and subse-
quently further refined by means of a hybrid algorithm, which reasons over time,
mechanism and chance, as follows. CAPRI’s overall scoring methods combine
topological constraints grounded on Patrick Suppes’ conditions of probabilis-
tic causation (see e.g., [44]), with a maximum likelihood-fit procedure (cfr., [28])
and derives much of its statistical power from the application of bootstrap proce-
dures (see e.g., [11]). CAPRI returns a graphical model of a complex selectivity
relation among events which captures the essential aspects of cancer evolution:
branches, confluences and independent progressions. In the specific case of
confluences, CAPRI’s ability to infer them is related to the complexity of the
“patterns” they exhibit, expressed in a logical fashion. As pointed out by other
approaches (cfr., [4]), this strategy requires trading off complexity for expressiv-
ity of the inferred models, and results in two execution modes for the algorithm:
supervised and unsupervised, which we discuss in details in Sections 2 and 3.
In Section 3 (Methods) we show that CAPRI enjoys a set of attractive prop-
erties in terms of its complexity, soundness and expressivity, even in the presence
of uniform noise in the input data – e.g., due to genetic heterogeneity and ex-
perimental errors. Although many other approaches enjoy similar asymptotic
properties, we show that CAPRI can compute accurate results with surpris-
ingly small sample sizes (cfr., Section 4). Moreover, to the best of our knowl-
edge, based on extensive synthetic data simulations, CAPRI outperforms all
the competing procedures with respect to all desirable performance metrics.
We conclude by showing an application of CAPRI to reconstruct a progression
model for atypical Chronic Myeloid Leukemia (aCML) using a recent exome
sequencing dataset, first presented in [41].
2For instance, epigenetic alterations such as methylation and alterations in gene expression
are not directly usable as input data for the algorithm. Notice that the selection of the relevant
events is beyond the scope of this work and requires a further upstream pipeline, such as that
provided, for instance, in [46,49].
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1.1 State of the Art
For an extensive review on cancer progression model reconstruction we refer
to the recent survey by [6]. In brief, progression models for cancer have been
studied starting with the seminal work of [48] where, for the first time, cancer
progression was described in terms of a directed path by assuming the existence
of a unique and most likely temporal order of genetic mutations. [48] manually
created a (colorectal) cancer progression from a genetic and clinical point of
view. More rigorous and complex algorithmic and statistical automated ap-
proaches have appeared subsequently. As stated already, the earliest thread of
research simply sought more generic progression models that could assume tree-
like structures. The oncogenetic tree model captured evolutionary branches of
mutations (cfr., [9, 45]) by optimizing a correlation-based score. Another pop-
ular approach to reconstruct tree structures appears in [10]. Other general
Markov chain models such as, e.g., [21] reconstruct more flexible probabilistic
networks, despite a computationally expensive parameter estimation. In [37],
we introduced an algorithm called CAncer PRogression Extraction with Single
Edges (CAPRESE), which, based on its extensive empirical analysis, may be
deemed as the current state-of-the-art algorithm for the inference of tree mod-
els of cancer progression. It is based on a shrinkage-like statistical estimation,
grounded in a general theoretical framework, which we extend further in this
paper. Other results that extend tree representations of cancer evolution exploit
mixture tree models, i.e., multiple oncogenetic trees, each of which can indepen-
dently result in cancer development (cfr., [5]). In general, all these methods are
capable of modeling diverging temporal orderings of events in terms of branches,
although the possibility of converging evolutionary paths is precluded.
To overcome this limitation, the most recent approaches tends to adopt
Bayesian graphical models, i.e., Bayesian Networks (BN). In the literature, there
have been two initial families of methods aimed at inferring the structure of a
BN from data (cfr., [28]). The first class of models seeks to explicitly capture all
the conditional independence relations encoded in the edges and will be referred
to as structural approaches; the methods in this family are inspired by the work
on causal theories by Judea Pearl (cfr., [39, 40, 43, 47]). The second class –
likelihood approaches – seeks a model that maximizes the likelihood of the data
(cfr., [7, 19,42]).
A more recent hybrid approach to learn a BN which combines the two fam-
ilies above by (i) constraining the search space of the valid solutions and, then,
(ii) fitting the model with likelihood maximization (see [4, 15, 34]). A further
technique to reconstruct progression models from cross-sectional data was in-
troduced in [3], in which the transition probabilities between genotypes are
inferred by defining a Moran process that describes the evolutionary dynamics
of mutation accumulation. In [8] this methodology was extended to account for
pathway-based phenotypic alterations.
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2 Approach
In what follows, we denote with P(·) and P(· | ·) the observed marginal and
conditional probability of an event, whose complement is denoted with the di-
acritical mark · (macron).
A probabilistic model of selective advantage. Central to CAPRI’s score
function is Suppes’ notion of probabilistic causation (cfr., [44]), which can be
stated in the following terms: a selectivity relation3 among two observables i and
j if (1) i occurs earlier than j – temporal priority (tp) – and (2) if the probability
of observing i raises the probability of observing j, i.e., P(j | i) > P(j | i) –
probability raising (pr). The definition of probability raising subsumes positive
statistical dependency and mutuality (see, e.g., [37]). Note that the resulting
relation (also, called prima facie causality) is purely observational and remains
agnostic to the possible mechanistic cause-effect relation involving i and j.
While Suppes’ definition of probabilistic causation has known limitations
in the context of general causality theory (see discussions in, e.g., [20, 26]), in
the context of cancer evolution, this relation appropriately describes various
features of selective advantage in somatic alterations that accumulate as tumor
progresses.
Thus, in our framework, we implement the temporal priority among events
– condition (1) – as P(i) > P(j), because it is intuitively sound to assume
that the (cumulative) genomic events occurring earlier are the ones present in
higher frequency in a dataset. In addition, condition (2) is implemented as is,
that is by requiring that for each pair of observables i and j directly connected,
P(j | i) > P(j | i) is verified. Taken together, these conditions gives rise to a
natural ordering relation among events, written “i B j” and read as “i has a
selective influence on j.” This relation is a necessary but not sufficient condition
to capture the notion of selective advantage, and additional constraints need to
be imposed to filter spurious relations. Spurious correlations are both intrinsic
to the definition (e.g., if iB jBw then also iBw, which could be spurious) and
to the model we aim at inferring, because data is finite as well as corrupted by
noise.
Building on this framework, we devise inference algorithms that capture the
essential aspects of heterogeneous cancer progressions: branching, independence
and convergence – all combining in a progression model.
Progression patterns. The complexity of cancer requires modeling multiple
non-trivial patterns of its progression: for a specific event, a pattern is defined
as a specific combination of the closest upstream events that confers a selective
advantage.
As an example, imagine a clonal subpopulation becoming fit – thus enjoying
expansion and selection – once it acquires a mutation of gene c, provided it also
3Suppes presents the relation in terms of causality; however, we avoid Suppes’ terminology
as we build on just two of his many axioms, which only give rise to the notion of prima-facie
causality.
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temporal priority
path P(a) > P(b) > P(c)
branch P(a) > P(b) > P(d) and P(a) > P(c)
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∧ ∧ ∧
real progression a b c
a b c
conjunctive
real transitivity sub-formula
genuine spurious
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d
d
temporal priority
co-occurrence P(a) > P(d) and P(b) > P(d) and P(c) > P(d)
Figure 2: Singleton and Co-occurrence Selectivity Patterns. Examples
of patterns that CAPRI can automatically extract without prior hypotheses.
(Top): A linear path and branching model (left) and corresponding singleton
selectivity patterns with infinite sample size (right). All the genuine connections
are shown (red and black, directed by the temporal priority), as well as edges
(purple, undirected) which might be suggested by the topology (or observations,
if data were finite). (Bottom): Example of conjunctive model (a and b and c).
The co-occurrence selectivity pattern is shown, with all true patterns and infinite
sample size. The topology is augmented by logical connectives; green arrows are
spurious patterns emerging from the structure of the true pattern a ∧ b ∧ cB d.
has previously acquired a mutation in a gene in the upstream a/b pathway. In
terms of progression, we would like to capture the trajectories: {a,¬b}, {¬a, b}
and {a, b} precedes c (where ¬ denotes the absence of an event in the gene).
To establish this analysis formally, we augment our model of selection in a
tumor with a language built from simple propositional logic formulas using the
usual Boolean connectives: namely, “and” (∧), “or” (∨) and “xor” (⊕). These
patterns can be described by formulæ in a propositional logical language, which
can be rendered in Conjunctive Normal Form (CNF). A CNF formula ϕ has
the following syntax: ϕ = c1 ∧ . . . ∧ cn, where each ci is a disjunctive clause
ci = ci,1 ∨ . . . ∨ ci,k over a set of literals, each literal representing an event or
its negation. Given this (rather obvious) pattern representation, we write the
conditions for selectivity with patterns as
ϕB e ⇐⇒ P(ϕ) > P(e) and [P(e | ϕ) > P(e | ϕ)] ; (1)
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with respect to the example above, patterns 4 could be a ∨ bB c and a⊕ bB c
In our framework the problem of reconstructing a probabilistic graphical
model of progression reduces to the following: for each input event e, assess a set
of selectivity patterns {ϕ1Be, . . . , ϕkBe}, filter the spurious ones, and combine
the rest in a direct acyclic graph (DAG)5, augmented with logical symbols.
Notice that while we broke down the progression extraction into a series of
sub-tasks, the problem remains complex: patterns are unknown, potentially
spurious, and exponential in formula size; data is noisy; patterns must allow
for “imperfect regularities”, rather than being strict6. To summarize, in our
setting we can model complex progression trajectories with branches (i.e., events
involved in various patterns), independent progressions (i.e., events without
common ancestors) and convergence (via CNF formulas). The framework we
introduce here is highly versatile, and to the best of our knowledge, it infers and
checks more complex claims than any cancer progression algorithms described
thus far (cfr., [9, 15,37]).
3 Methods
Building on the framework described in the previous section, we now describe the
implementation of CAPRI’s building blocks. Notice that, in general, the infer-
ence of cancer progression models requires a complex data processing pipeline, as
summarized in Figure 3; its architecture optimally exploits CAPRI’s efficiency.
Assumptions. CAPRI relies on the following assumptions: i) Every pattern
is expressible as a propositional CNF formula; ii) All events are persistent, i.e.,
an acquired mutation cannot disappear; iii) All relevant events in tumor pro-
gression are observable, with the observations describing the progressive phe-
nomenon in an essential manner (i.e., closed world assumption, in which all
events ‘driving’ the progression are detectable); iv) All the events have non-
degenerate observed probability in (0, 1); v) All events are distinguishable, in
the following sense: input alterations produce different profiles across input
samples. Assumptions i-ii) relate to the framework derived in previous sec-
tion, while iii) imposes an onerous burden on the experimentalists, who must
select the relevant genomic events to model7. Assumption iv) relates instead
4Note that the conjunction ∧ in our setting is interpreted differently from the classical
notion (and the one adopted in e.g., [15]) since a ∧ b B c implies a B c and b B c in our
framework. See also [6]. Moreover, note that the scope of this study is intentionally kept
limited from further generalization of formulæ i.e., we will not consider statements of the
form ϕi B ϕj , where the rightmost argument is a formula too.
5A DAG is formed by a set of nodes and oriented edges connecting one node to another,
such that there are no directed loops among them. See SI Section 1 for a technical definition.
6This statement implies that there could be samples – i.e., patients – contradicting a
pattern which still remains valid at a population level. For this reason a pattern x ∧ y B z is
sometimes called a “noisy and”.
7Theoretically, this assumption - common to other Bayesian learning problems - is necessary
to prove CAPRI’s ability to extract the exact model in the optimal case of infinite samples.
Practically, as all relevant events are hardly selectable a priori and sample size is finite, further
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Figure 3: Data processing pipeline for cancer progression inference. We
sketch a pipeline to best exploit CAPRI’s ability to extract cancer progression
models from cross-sectional data. Initially, one collects experimental data (which
could be accessible through publicly available repositories such as TCGA) and
performs genomic analyses to derive profiles of, e.g., somatic mutations or Copy-
Number Variations for each patient. Then, statistical analysis and biological
priors are used to select events relevant to the progression and imputable by
CAPRI - e.g., driver mutations. To exploit CAPRI’s supervised execution mode
(see Methods) one can use further statistics and priors to generate patterns of
selective advantage - , e.g, hypotheses of mutual exclusivity. CAPRI can extract
a progression model from these data and assess various confidence measures on
its constituting relations - e.g., (non-)parametric bootstrap and hypergeometric
testing. Experimental validation concludes the pipeline.
to the statistical distinguishability of the input events (see the next section on
CAPRI’s Data Input). .
Trading Complexity for Expressivity. To automatically extract the pat-
terns that underly a progression model, one may try to adopt a brute-force
method of enumerating and testing all possibilities. This strategy is computa-
tionally intractable, however, since the number of (distinct) (sub)formulæ grows
exponentially with the number of events included in the model. Therefore, we
need to exploit certain properties of the B relation whenever possible, and trade
expressivity for complexity in other cases, as explained below.
Note that singleton and co-occurrence (∧) types of patterns are amenable
to compositional reasoning : if i1 ∧ . . .∧ ik B j then, for any p = 1, . . . , k, ip B j.
This observation leads to the following straightforward strategy of evaluating
every conjunctive (and henceforth singleton) relation using a pairwise-test for
the selectivity relation (see Figure 2).
Unfortunately, it is easy to see that this reasoning fails to generalize for
CNF patterns: e.g., when the pattern contains disjunctive operators (∨). As an
statistics can be used to select the most relevant driver alterations – see also Section 4, Results
and Discussion. Nonetheless, CAPRI can provide significant results even if this assumption
is not or cannot be verified.
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example, consider pattern a∨ bB c, in a cancer where {a,¬b} progression to c is
more prevalent than {¬a, b} and {a, b}. In this case, considering sub-formulas
only we might find a B c but miss b B c because the probability of mutated b
is smaller than that of c, thus invalidating condition (1) of relation B. Notice
that in extreme situations, when the data is very noisy, the algorithm may even
“invert” the selectivity relation to cB b.
This difficulty is not a peculiarity of our framework, but rather intrinsic
to the problem of extracting complex “causal networks” (cfr., [26, 39, 40]). To
handle this situation, CAPRI adapts a strategy that trades complexity for ex-
pressivity: the resulting inference procedure, Algorithm 1, can be executed in
two modes: unsupervised and supervised. In the former, inferred patterns of
confluent progressions are constrained to co-occurrence types of relations, in the
latter CAPRI can test more complex patterns, i.e., disjunctive or “mutual exclu-
sive” ones, provided they are given as prior hypotheses. In both cases, CAPRI’s
complexity – studied in next sections – is quadratic both in the number of events
and hypotheses.
Data Input (Step 1). CAPRI (cfr., Algorithm 1) requires an input set G of
n events, i.e., genomic alterations, and m cross-sectional samples, represented
as a dataset in an m×n binary matrix D, in which an entry Di,j = 1 if the event
j was observed in sample i, and 0 otherwise. Assumption iv) is satisfied when
all columns in D differ - i.e., the alteration profiles yield different observations.
Optionally, a set of k input hypotheses Φ = {ϕ1 B e1, . . . , ϕk B ek}, where
each ϕi is a well-formed
8 CNF formula. Note that we advise that the algorithm
be used in the following regime 9: k + n m.
Data Preprocessing (Lifting, step 2). When input hypotheses are pro-
vided (e.g., by a domain expert), CAPRI first performs a lifting operation over
D to permit direct inference of complex selectivity relations over a joint represen-
tation, which involve input events as well as the hypotheses. Lifting operation
evaluates each input CNF formula – for all input hypotheses in Φ – and out-
puts a lifted matrix D(Φ) to be processed further as in step 1. As an example,
consider hypothesis a⊕ bB c lifted input matrix D is:
D(Φ) =

a b c a⊕ bB c
1 1 1 1⊕ 1 = 0
1 0 1 1⊕ 0 = 1
0 1 0 0⊕ 1 = 1
1 0 1 1⊕ 0 = 1
 .
8Formally, we require that ϕi 6v ei, where v represents the usual syntactical ordering
relation among atomic events and formulas, and disallows for example a ∨ b B a.
9In the current biomedical setting, the number of samples (m) is usually in the hundreds,
while number of possible mutations (n) and hypotheses (k), absent any pre-processing, could
be large, thus violating the assumption; in these cases, we rely on various commonly used
pre-preprocessing filters to limit n to driver mutations, and k to simple hypotheses involving
the driver mutations. However, in the future as the number of samples increases, we envision
a more agnostic application.
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Note that the first row (profile {a, b, c} ) contradicts the hypothesis, while all
other rows support it.
Selectivity Topology (steps 3, 4, 5). We exploit a compositional approach
to test CNF hypotheses as follows: the disjunctive relations are grouped, and
treated as if they were individual objects in G. For example, when a formula
ϕB d where ϕ = (a∨ b)∧ c is considered, we assess ϕB d as whether (a∨ b)B d
and c B d hold – with the proviso that we treat (a ∨ b) as an individual event.
Formally, with clauses (ϕ) we denote the disjunctive clauses in a CNF formula.
Nodes in the reconstruction are all input events together with all the dis-
junctive clauses of each input formula ϕ.
Edges in the reconstructed DAG are patterns that satisfy both conditions (1)
and (2) of the selectivity relation B. Formally, CAPRI includes an edge between
two nodes ϕ and j only if both Γϕ,j = P(ϕ)−P(j) and Λϕ,j = P(j | ϕ)−P(j | ϕ)
are strictly positive. Note that ϕ can be both a disjunctive clause as well
as a singleton event. A function pi(·) assigns a parent to each node that is
not an input formula. Note that this approach works efficiently by nature of
the lifted representation of D. The reconstructed DAG contains all the true
positive patterns, with respect to B, plus spurious instances of B which CAPRI
subsequently removes in step 6 (cfr., the Supplementary Material for a proof of
this statement).
Note that D can be readily interpreted as a probabilistic graphical model,
once it is augmented with a labeling function α : N → [0, 1], whereN is the set of
nodes – i.e., the genetic alterations – such that α(i) is the independent probability
of observing mutation i in a sample, whenever all of its parent mutations (i.e.,
pi(i)) are observed (if any). Thus D induces a distribution of observing a subset
of events in a set of samples (i.e., a probability of observing a certain mutational
profile in a patient).
Maximum Likelihood Fit (step 6). As the selectivity relation provides
only a necessary condition, we must filter out all of its spurious instances that
might have been included in D (i.e., the possible false positives).
For any selectivity structure, spurious claims contribute to a reduction in the
likelihood-fit relative to true patterns. Thus, a standard maximum-likelihood fit
can be used to select and prune the selectivity DAG (including a regularization
term to avoid over-fitting10). Here, we adopt the Bayesian Information Cri-
terion (BIC), which implements Occam’s razor by combining log-likelihood fit
with a penalty criterion proportional to the log of the DAG size via Schwarz
Information Criterion (see [42]). The BIC score is defined as follows.
bic (D, D(Φ)) = LL (D, D(Φ))− logm
2
dim(D). (2)
10In principle other regularisation strategies common to Bayesian learning could be used,
e.g., Akaike information criterion (see [7] and references therein). In this paper, we prefer to
work with BIC which, in general, trades model complexity to reduce false positives rate.
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Algorithm 1 CAncer PRogression Inference (CAPRI)
1: Input: A set of events G = {g1, . . . , gn}, a matrix D ∈ {0, 1}m×n and k CNF causal claims
Φ = {ϕ1 B e1, . . . , ϕk B ek} where, for any i, ei 6v ϕi and ei ∈ G;
2: [Lifting] Define the lifting of D to D(Φ) as the augmented matrix
D(Φ) =

D1,1 . . . D1,n ϕ1(D1,·) . . . ϕk(D1,·)
.
.
.
. . .
.
.
.
.
.
.
. . .
.
.
.
Dm,1 . . . Dm,n ϕ1(Dm,·) . . . ϕk(Dm,·)
 .
by adding a column for each ϕi B ci ∈ Φ, with ϕi evaluated row-by-row. Define then the
coefficients Γi,j = P(i)− P(j) and Λi,j = P(j | i)− P(j | i) pairwise over D(Φ);
3: [DAG nodes] Define the set of nodes N = G ∪
(⋃
ϕi
clauses (ϕi)
)
which contains both input
events and the disjunctive clauses in every input formula of Φ.
4: [DAG edges] Define a parent function pi where pi(j 6∈ G) = ∅ – avoid edges incoming in a
formula 11– and
pi(j ∈ G) = {i ∈ G | Γi,j ,Λi,j > 0}
∪ {clauses (ϕ) | Γϕ,j ,Λϕ,j > 0, ϕB j ∈ Φ} . (3)
Set the DAG to D = (N, pi).
5: [DAG labeling] Define the labeling α as follows
α(j) =
{
P(j), if pi(j) = ∅ and j ∈ G;
P(j | i1 ∧ . . . ∧ in), if pi(j) = {i1, . . . , in}.
6: [Likelihood fit] Filter out all spurious causes from D by likelihood fit with the regularization
BIC score and set α(j) = 0 for each removed edge.
7: Output: the DAG D and α;
Here, D(Φ) is the lifted input matrix, m denotes the number of samples and
dim(D) is the number of parameters in the model D. Because, in general, dim(·)
depends on the number of parents each node has, it is a good metric for model
complexity. Moreover, since each edge added to D increases model complexity,
the regularization term based on dim(·) favors graphs with fewer edges and,
more specifically, fewer parents for each node.
At the end of this step, D and the labeling function are modified accordingly,
based on the result of BIC regularization. By collecting all the incoming edges
in a node it is possible to extract the patterns, which have been selected by
CAPRI as the positive ones.
Inference Confidence: Bootstrap and Statistical Testing. To infer con-
fidence intervals of the selectivity relations B, CAPRI employs bootstrap with
11Although CAPRI is equipped with bootstrap testing it is still possible to encounter various
degenerate situations. In particular, for some pair of events it could be that temporal priority
cannot be satisfactorily resolved, i.e. there is no significant p-value for any edge orientation.
Thus, loops might be present in the inferred prima facie topology. Nonetheless, some of these
could be still disentangled by probability raising, while some might remain, albeit rarely. To
remove such edges we suggest to proceed as follows: (i) sort these edges according to their
p-value (considering both temporal priority and probability raising), (ii) scan the sorted list
in decreasing order of confidence, (iii) remove an edge if it forms a loop.
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rejection resampling as follows, by estimating a distribution of the marginal
and joint probabilities. For each event, (i) CAPRI samples with repetitions
rows from the input matrix D (bootstrapped dataset), (ii) CAPRI next esti-
mates the distributions from the observed probabilities, and finally, (iii) CAPRI
rejects values which do not satisfy 0 < P(i) < 1 and P(i | j) < 1 ∨ P(j | i) < 1,
and iterates restarting from (i). We stop when we have, for each distribution,
at least K values (in our case K = 100). Any inequality (i.e., checking temporal
priority and probability raising) is estimated using the non-parametric Mann-
Whitney U test12 with p-values set to 0.05. We compute confidence p-values for
both temporal priority and probability raising using this test, which need not
assume Gaussian distributions for the populations.
Once a DAG D is inferred both parametric and non-parametric bootstrapping
methods can be used to assign a confidence level to its respective pattern and
to the overall model. Essentially, these tests consist of using the reconstructed
model (in the parametric case), or the probabilities observed in the dataset (in
the non-parametric case) to generate new synthetic datasets, which are then
reused to reconstruct the progressions (see, e.g., [12] for an overview of these
methods). The confidence is estimated by the number of times the DAG or any
instance of B is reconstructed from the generated data.
Complexity, Correctness and Expressivity. CAPRI has the following
asymptotic complexity (Theorem 1, SI Section 2):
(i) Without input hypotheses the execution is self-contained and polynomial
in the size of D.
(ii) In addition to the above cost, CAPRI tests input hypotheses of Φ at a
polynomial cost in the size of |Φ|. In this case, however, its complexity may
range over many orders of magnitude depending on the structural complexity
of the input set Φ consisting of hypotheses.
An empirical analysis of the execution time of CAPRI and the competing
techniques on synthetic datasets is provided in the SI, Section 3.5.
CAPRI is a sound and complete algorithm, and its expressivity in terms of
the inferred patterns is proportional to the hypothesis set Φ which, in turn,
determines the complexity of the algorithm. With a proper set of input hypoth-
esis, CAPRI can infer all (and only) the true patterns from the data, filtering
out all the spurious ones (Theorem 2, SI Section 2).Without hypotheses, besides
singleton and co-occurrence, no other patterns can be inferred (see Figure 2).
Also, some of these claims might be spurious in general for more complex (and
unverified) CNF formula (Theorem 3, SI Section 2).
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Figure 4: Comparative Study. Performance and accuracy of CAPRI (un-
supervised execution) and other algorithms, IAMB, PC, BIC, BDE, CBN and
CAPRESE, were compared using synthetic datasets sampled by a large number
of randomly parametrized progression models – trees, forests, connected and dis-
connected DAGs, which capture different aspects of confluent, branched and het-
erogenous cancer progressions. For each of those, 100 models with n = 10 events
were created and 10 distinct datasets were sampled by each model. Datasets
vary by number of samples (m) and level of noise in the data (ν) – see the
Supplementary Information file for details. (Red box ) Average Hamming dis-
tance (HD) – with 1000 runs – between the reconstructed and the generative
model, as a function of dataset size (m ∈ {50, 100, 150, 200, 500, 1000}), when
data contain no noise (ν = 0). The lower the HD, the smaller is the total
rate of mis-inferred selectivity relations among events. (Blue box ) The same is
shown for a fixed sample set size m = 100 as a function of noise level in the
data (ν ∈ {0, 0.025, 0.05, · · · , 0.2}) so as to account for input false positives and
negatives. See SI Section 3 for more extensive results on precision and recall
scores and also including additional combinations of noise and samples as well
as experimental settings.
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4 Results and Discussion
To determine CAPRI’s relative accuracy (true-positives and false-negatives)
and performance compared to the state-of-the-art techniques for network in-
ference, we performed extensive simulation experiments. From a list of po-
tential competitors of CAPRI, we selected: Incremental Association Markov
Blanket (IAMB, [47]), the PC algorithm (see [43]), Bayesian Information Cri-
terion (BIC, [42]), Bayesian Dirichlet with likelihood equivalence (BDE, [19])
Conjunctive Bayesian Networks (CBN, [15]) and Cancer Progression Inference
with Single Edges (CAPRESE, [37]). These algorithms constitute a rich land-
scape of structural methods (IAMB and PC), likelihood scores (BIC and BDE)
and hybrid approaches (CBN and CAPRESE).
Also, we applied CAPRI to the analysis of an atypical Chronic Myeloid
Leukemia dataset of somatic mutations with data based on [41].
4.1 Synthetic data
We performed extensive tests on a large number of synthetic datasets generated
by randomly parametrized progression models with distinct key features, such
as the presence/absence of: (1) branches, (2) confluences with patterns of co-
occurrence, (3) independent progressions (i.e., composed of disjoint sub-models
involving distinct sets of events). Accordingly, we distinguish four classes of
generative models with increasing complexity and the following features:
trees forests connected DAGs disconnected DAGs
(1) 3 3 3 3
(2) 7 7 3 3
(3) 7 3 7 3
The choice of these different type of topologies is not a mere technical ex-
ercise, but rather it is motivated, in our application of primary interest, by
heterogeneity of cancer cell types and possibility of multiple cells of origin.
To account for biological noise and experimental errors in the data we intro-
duce a parameter ν ∈ (0, 1) which represents the probability of each entry to be
random in D, thus representing a false positive (+) and a false negative rate
(−): + = − = ν/2 . The noise level complicates the inference problem, since
samples generated from such topologies will likely contain sets of mutations that
are correlated but causally irrelevant.
To have reliable statistics in all the tests, 100 distinct progression models
per topology are generated and, for each model, for every chosen combination
of sample set size m and noise rate ν, 10 different datasets are sampled (see SI
Section 3 for our synthetic data generation methods).
Algorithmic performance was evaluated using the metrics Hamming distance
(HD), precision and recall, as a function of dataset size, + and −. HD measures
12The Mann-Whithney U test is a rank-based non-parametric statistical hypothesis test
that can be used as an alternative to the Student’s t-test and is particularly useful if data are
not normally distributed.
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the structural similarity among the reconstructed progression and the generative
model in terms of the minimum-cost sequence of node edit operations (inclusion
and exclusion) that transforms the reconstructed topology into the generative
one13. Precision and recall are defined as follows: precision = TP/(TP +
FP) and recall = TP/(TP + FN), where TP are the true positives (number of
correctly inferred true patterns), FP are the false positives (number of spurious
patterns inferred) and FN are the false negatives (number of true patterns that
are not inferred ). The closer both precision and recall are to 1, the better.
In Figure 4 we show the performance of CAPRI and of the competing tech-
niques, in terms of Hamming distance, on datasets generated from models with
10 events and all the four different topologies. In particular, we show the per-
formance: (i) in the case of noise-free datasets, i.e., ν = 0 and different values
of the sample set size m and (ii) in the case of a fixed sample set size, m = 100
(size that is likely to be found in currently available cancer databases, such as
TCGA (cfr., [36])) and different values of the noise rate ν. As is evident from
Figure 4 CAPRI outperforms all the competing techniques with respect to all
the topologies and all the possible combinations of noise rate and sample set size,
in terms of average Hamming distance (with the only exception of CAPRESE
in the case of tree and forests, which displays a behavior closer to CAPRI’s).
The analyses on precision and recall display consistent results (SI Section 3).
In other words, we demonstrate on the basis of extensive synthetic tests that
CAPRI requires a much lower number of samples than the other techniques in
order to converge to the real generative model and also that it is much more ro-
bust even in the presence of significant amount of noise in the data, irrespective
of the underlying topology.
See SI Section 3 for a more complete description of the performance evalu-
ation for all the analyzed combinations of parameters. There, we have shown
that CAPRI is highly effective when the co-occurrence constraint on confluences
is relaxed to disjunctive patterns, even if no input hypotheses are provided, i.e.,
Φ = ∅. This result hints at CAPRI’s robustness to infer patterns with imperfect
regularities. Finally, we also show that CAPRI is effective in inferring synthetic
lethality relations in this case using the operator ⊕ as introduced in Section 2,
Approach; when a combination of mutations in two or more genes leads to
cell death, while separately, the mutations are viable. In this case, candidate
relations are directly input as Φ.
4.2 Atypical Chronic Myeloid Leukemia (aCML)
As a case study, we applied CAPRI to the mutational profiles of 64 aCML
patients described in [41]. Through exome sequencing, the authors identify a
recurring missense point mutation in the SET-binding protein 1 (setbp1) gene
as a novel aCML marker.
13This measure corresponds to the sum of false positives and false negative and, for a set
of n events, is bounded above by n(n − 1) when the reconstructed topology contains all the
false negatives and positives.
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atypical Chronic Myeloid Leukemia (transposed matrix)
 n = 64    m = 16    |G| = 9
22% SETBP1
14% ASXL1
11% EZH2
11% TET2
8% NRAS
8% TET2
8% CSF3R
8% ASXL1
6% TET2
5% CBL
5% IDH2
5% CSF3R
3% EZH2
2% EZH2
2% CBL
2% SF3B1
hits hits
4
0
SETBP1 TET2 EZH2
CBL
TET2
SF3B1
EZH2 CBLASXL1ASXL1
28%     < .01 30%     0.08 36%     < .01 18%     0.06
7%     < .01
Events type
Ins/Del
Missense point
Nonsense point
 
Patterns
Exclusivity (hard)
Events frequency
2%   EZH2 (min)
22% SETBP1 (max)
 
Sample size
n = 64
m = 16
|G| = 9
Figure 5: Atypical Chronic Myeloid Leukemia. (left) Mutational profiles of
n = 64 aCML patients - exome sequencing in [41] - with alterations in |G| = 9
genes with either mutation frequency > 5% or belonging to an hypothesis in-
puted to CAPRI (SI Section 4). Mutation types are classified as nonsense point,
missense point and insertion/deletions, yielding m = 16 input events. Purple
annotations report the frequency of mutations per sample. (right) Progression
model inferred by CAPRI in supervised mode. Node size is proportional to
the marginal probability of each event, edge thickness to the confidence esti-
mated with 1000 non-parametric bootstrap iterations (numbers shown leftmost
of every edge). The p-value of the hypergeometric test is displayed too. Hard
exclusivity patterns inputed to CAPRI are indicated as red squares. Events
without inward/outward edges are not shown.
Among all the genes present in the dataset by Piazza et al., we selected
those either (i) mutated - considered any mutation type - in at least 5% of the
input samples (3 patients), or (ii) hypothesised to be part of a functional aCML
progression pattern in the literature 14. The input dataset with selected events
is shown in Figure 5; notice that somatic mutations are categorised as indel,
missense point and nonsense point as in [41]. In Figure 5 we show the model
reconstructed by CAPRI (supervised mode, execution time ≈ 5 seconds) on this
dataset, with confidence assessed via 1000 non-parametric bootstrap iterations.
The model highlights several non trivial selectivity relations involving genomic
events relevant to aCML development.
First, CAPRI predicts a progression involving mutations in setbp1, asxl1
and cbl, consistently with the recent study by [32], in which these genes were
shown to be highly correlated and possibly functioning in a synergistic manner
for aCML progression. Specifically, CAPRI predicts a selective advantage rela-
tion between missense point mutations in setbp1 and nonsense point mutations
in asxl1. This is in line with recent evidence from [24] suggesting that setbp1
mutations are enriched among asxl1-mutated myelodysplastic syndrome (MDS)
14Two hard exclusivity patterns - i.e., mutual exclusivity with “xor” - were tested, involving
the mutations of: (i) genes asxl1 and sf3b1 (see [30]), which is present in the inferred
progression model in Figure 5, and (ii) genes tet2 and idh2 (see [13]). The syntax in which
the patterns are expressed is in the SI, Section 4.
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patients, and in-vivo experiments point to a driver role of setbp1 for that
leukemic progression. Interestingly, our model seems also to suggest a different
role of asxl1 missense and nonsense mutation types in the progression, yet
more extensive studies (e.g., prospective or systems biology explanation) are
needed to corroborate this hypothesis.
Among the hypotheses given as input to CAPRI, the algorithm seems to
suggest that the exclusivity pattern among asxl1 and sf3b1 mutations selects
for cbl missense point mutations. The role of the asxl1/sf3b1 exclusivity
pattern is consistent with the study of [30] which shows that, on a cohort of 479
MDS patients, mutations in sf3b1are inversely related to asxl1 mutations.
Also, in [1] it was recently shown that asxl1 mutations, in patients with
MDS, myeloproliferative neoplasms (MPN) and acute myeloid leukemia, most
commonly occur as nonsense and insertion/deletion in a clustered region ad-
jacent to the highly conserved PHD domain (see [14]) and that mutations of
any type eventually result in a loss of asxl1 expression. This observation is
consistent with the exclusivity pattern among asxl1 mutations in the recon-
structed model, possibly suggesting alternative trajectories of somatic evolution
for aCML (involving either asxl1 nonsense or indel mutations).
Finally, CAPRI predicts selective advantage relations among tet2 and ezh2
missense point and indel mutations. Even though the limited sample size does
not allow to draw definitive conclusions on the ordering of such alterations,
we can hypothesize that they may play a synergistic role in aCML progres-
sion. Indeed, [35] suggests that the concurrent loss of ezh2 and tet2 might
cooperate in the pathogenesis of myelodysplastic disorders, by accelerating the
overall tumor development, with respect to both MDSs and overlap disorders
(MDS/MPN).
5 Conclusions
The reconstruction of cancer progression models is a pressing problem, as it
promises to highlight important clues about the evolutionary dynamics of tu-
mors and to help in better targeting therapy to the tumor (see e.g., [38]). In
the absence of large longitudinal datasets, progression extraction algorithms
rely primarily on cross-sectional input data, thus complicating the statistical
inference problem.
In this paper we presented CAPRI, a new algorithm (and part of the TRONCO
package) that attacks the progression model reconstruction problem by inferring
selectivity relationships among “genetic events” and organizing them in a graph-
ical model. The reconstruction algorithm draws its power from a combination
of a scoring function (using Suppes’ conditions) and subsequent filtering and re-
fining procedures, maximum-likelihood estimates and bootstrap iterations. We
have shown that CAPRI outperforms a wide variety of state-of-the-art algo-
rithms. We note that CAPRI performs especially well in the presence of noise
in the data, and with limited sample size. Moreover we note that, unlike other
approaches, CAPRI can reconstruct different types of confluent trajectories un-
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affected by the irregularities in the data – the only limitation being our ability
to hypothesize these patterns in advance. We also note that CAPRI’s overall
algorithmic complexity and convergence properties do offer several tradeoffs to
the user.
Successful cancer progression extraction is complicated by tumor heterogene-
ity: many tumor types have molecular subtypes following different progression
patterns. For this reason, it can be advantageous to cluster patient samples by
their genetic subtype prior to applying CAPRI. Several tools have been devel-
oped that address this clustering problem (e.g., Network-based stratification [22]
or COMET from [29]). A related problem is the classification of mutations into
functional categories. In this paper, we have used genes with deleterious muta-
tions as driving events. However, depending on other criteria, such as the level
of homogeneity of the sample, the states of the progression can represent any set
of discrete states at varying levels of abstraction. Examples include high-level
hallmarks of cancer proposed by [17,18], a set of affected pathways, a selection of
driving genes, or a set of specific genomic aberrations such as genetic mutations
at a more mechanistic level.
We are currently using CAPRI to conduct a number of studies on publicly
available datasets (mostly from TCGA, [36]) in collaboration with colleagues
from various institutions. In this work we have shown the results of the recon-
struction on the aCML dataset published by [41], and in SI Section 4 we include
a further example application on ovarian cancer ( [27]), as well as a compar-
ative study against the competing techniques. Furthermore, we are currently
extending our pipeline in order to include pre-processing functionalities, such as
patient clustering and categorization of mutations/genes into pathways (using
databases such as the KEGG database (see [25]) and functionalities from tools
like Network-based clustering, due to [22].
Encouraged by CAPRI’s ability to infer interesting relationships in a complex
disease such as aCML, we expect that in the future CAPRI will help uncover
relationships to aid our understanding of cancer and eventually improve targeted
therapy design.
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